EICHORCondition: Cervical Cancer · Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.
This description comes directly from the study's public registry record.
Lingying Wu, Professor · +8601067781331 · wulingying@csco.org.cn
Huijuan Yang, Professor · +8602164175590 · huijuanyang@hotmail.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06692166